

Arden and Greater East Midlands Commissioning Support Unit in association with  
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,  
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

## Lincolnshire *PACE* Shorts

Summary of PACEF decisions from September 2015

For further details see *PACE Bulletin* Volume 9 No 15 (September 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Canagliflozin 100mg and 300mg tablets (Invokana) (Janssen Cilag)	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	<p>Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN.</p> <p>Also approved by NICE for triple therapy in combination with metformin and a sulfonylurea or metformin and pioglitazone; designation GREEN. Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN.</p> <p>Also approved by NICE for triple therapy in combination with metformin and a sulfonylurea or metformin and pioglitazone; designation GREEN.</p> <p>Not recommended by NICE for monotherapy; RED-RED for this indication.</p> <p><b>Included in the Lincolnshire Joint Formulary for use within NICE criteria.</b></p>
Cefixime 200mg tablets (Suprax) (Sanofi)	For respiratory tract infections and urinary tract infections	RED for prescribing by Sexual Health only. Included in the Lincolnshire Joint Formulary.
Chloramphenicol 250mg capsules	Reserved for the treatment of life-threatening infections, particularly those caused by Haemophilus influenza and also typhoid fever	RED Included in the Lincolnshire Joint Formulary.
Cilostazol tablets 50mg and 100mg (Pletal)	Improvement of maximal and pain free walking distances in patients with intermittent claudication who do not have rest pain or evidence of peripheral tissue necrosis	RED-RED Removed from the Lincolnshire Joint Formulary for this indication.
Dapagliflozin (Forxiga) 5mg and 10mg tablets	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	<p>Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN.</p> <p>Not recommended by NICE for monotherapy; RED-RED for this indication.</p> <p><b>Included in the Lincolnshire Joint Formulary for use within NICE criteria.</b></p>
Empagliflozin (Jardiance) 10mg and 20mg tablets	In adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	<p>Recommended as a treatment option when an SGLT2 inhibitor is indicated in combination with metformin; designation GREEN.</p> <p>Also approved by NICE for triple therapy in combination with metformin and a sulfonylurea or metformin and pioglitazone; designation GREEN.</p>

		<p>Not recommended by NICE for monotherapy; RED-RED for this indication.</p> <p><b>Included in the Lincolnshire Joint Formulary for use within NICE criteria.</b></p>
Everolimus 250microgram, 500microgram and 750microgram tablets (Certican) (Novartis)	For use in combination with tacrolimus and corticosteroids for prophylaxis of organ rejection in liver transplant patients.	<p>RED-RED</p> <p>Not approved for use through the Lincolnshire Joint Formulary for this indication.</p>
Fidaxomicin tablets 200mg (Dificlir) (Astellas)	For C.difficile infection	<p>AMBER without shared care subject to recommendation by a microbiologist.</p> <p>Joint Formulary status changed from RED to AMBER.</p>
Fosfomycin 3g sachets (unlicensed)	For use on the advice of a microbiologist for the treatment of uncomplicated lower urinary tract infections caused by multiple antibacterial resistant organisms when other antibacterials cannot be used	<p>AMBER (without shared care); can be prescribed by a GP subject to microbiologist advice and availability in primary care.</p> <p>Joint Formulary status changed from RED to AMBER.</p>
Latanoprost 50 microgram per ml eye drops (generic)	For the treatment of open angle glaucoma and ocular hypertension	<p>AMBER subject to initiation by an ophthalmologist.</p> <p>First line for the treatment of glaucoma and ocular hypertension, particularly in those with early mild disease.</p> <p>Included in the Lincolnshire Joint Formulary.</p>
Latanoprost 50 microgram per ml eye drops (Xalatan) (Pfizer)	For the treatment of open angle glaucoma and ocular hypertension.	<p>RED-RED.</p> <p>Should be prescribed generically.</p>
Linezolid 600mg tablets (Zyvox) (Pfizer)	For nosocomial pneumonia, community acquired pneumonia and complicated SSTI in a hospital environment.	<p>RED</p> <p>Included in the Lincolnshire Joint Formulary.</p>
Naftidrofuryl 100mg capsules (generic/ Praxilene)	Peripheral vascular disorders	<p>GREEN</p> <p>Generic prescribing preferred.</p> <p>Included in the Lincolnshire Joint Formulary for this indication.</p>
Nintedanib 100mg and 150mg capsules (Vargatef)	For use in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.	<p>RED</p> <p>Approved for Inclusion in the Lincolnshire Joint Formulary for this indication.</p>

Nintedanib 100mg and 150mg capsules (Ofev)	For use in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).	RED-RED subject to future assessment. Not currently included for use through the Lincolnshire Joint Formulary
Omalizumab 150mg per ml solution for injection in pre-filled syringe (Xolair) (Novartis)	For use as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment and leukotriene antagonists.  For use in patients (adults, adolescents and children (6 to <12 years of age) with convincing IgE (immunoglobulin E) mediated asthma.	RED Approved for Inclusion in the Lincolnshire Joint Formulary for this indication. Should only be initiated within specialist centres.  RED Included in the Lincolnshire Joint Formulary for this indication.
Pomalidomide 1mg, 2mg 3mg and 4mg capsules (Imnovid) (Celgene)	For use in combination with dexamethasone in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	RED-RED Not approved for use through the Lincolnshire Joint Formulary for this indication.
Ustekinumab injection (Stelara) (Janssen-Cilag)	For use alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.	RED Approved for Inclusion in the Lincolnshire Joint Formulary for this indication. For use only under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriatic arthritis.
Vancomycin capsules 125mg and 250mg	For pseudomembranous colitis and staphylococcal enterocolitis	AMBER without shared care subject to recommendation by a microbiologist. Joint Formulary status changed from RED to AMBER.
Vedolizumab 300mg injection (Entyvio) (Takeda)	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF $\alpha$ ) antagonist.  For the treatment of adult patients with moderate to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF $\alpha$ ) antagonist.	RED Approved for Inclusion in the Lincolnshire Joint Formulary for this indication. The license stipulates that treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis.  RED-RED for this indication pending publication of NICE guidance.
Voriconazole 50mg and 200mg tablets (Vfend) (Pfizer)	For the treatment of invasive aspergillosis, candidaemia in non-neutropenic patients, fluconazole resistant serious invasive Candida infections (including C. krusei), serious fungal infections caused by Scedosporium spp and Fusarium spp in patients with progressive possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic haematopoietic stem cell transplant	RED Included in the Lincolnshire Joint Formulary for these indications.

	recipients.	
--	-------------	--

**RED-RED:** This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

**RED:** This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

**AMBER:** This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

**GREEN:** This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on [sandra.france@gemcsu.nhs.uk](mailto:sandra.france@gemcsu.nhs.uk).

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at [www.lincolnshirejointformulary.nhs.uk](http://www.lincolnshirejointformulary.nhs.uk)

**THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION**